Hawryluk P. Kent 4

What Happened

• P. Kent Hawryluk, President & CEO and Director of MBX Biosciences (MBX), sold 607 shares of common stock on 2026-05-06. The weighted average sale price reported is $29.54 per share, for aggregate proceeds of approximately $17,931.
• This transaction was a sale executed to cover tax obligations associated with the vesting of restricted stock units (RSUs), a routine sell-to-cover action rather than an outright investment decision.

Key Details

• Transaction date: 2026-05-06; Form 4 filed: 2026-05-08 (appears timely — within the typical 2 business day window).
• Price: $29.54 weighted average; reported sale prices ranged from $29.23 to $29.88. The filer offers to provide the per-price breakdown on request.
• Shares sold: 607; Proceeds: ~$17,931.
• Shares held after transaction: Not specified in the provided summary.
• Footnotes of note:
  • Mandatory sell-to-cover to satisfy tax withholding on RSU vesting.
  • Weighted-average price with a disclosed range ($29.23–$29.88); detailed per-price breakdown available on request.
  • Some shares are held by a revocable trust of which the reporting person is trustee; the filer disclaims beneficial ownership of those trust shares except to the extent of any pecuniary interest.

Context

• Sell-to-cover transactions are common when RSUs vest; they are used solely to pay tax withholding and are generally considered routine rather than a signal about the insider’s view of the company.
• For retail investors, purchases are usually more informative about insider confidence than routine sales to cover taxes.